<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with selegiline</title>
<meta name="Author" content="gts (gts_2000@yahoo.com)">
<meta name="Subject" content="RE: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-17">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with selegiline</h1>
<!-- received="Mon Feb 17 13:45:37 2003" -->
<!-- isoreceived="20030217204537" -->
<!-- sent="Mon, 17 Feb 2003 15:46:50 -0500" -->
<!-- isosent="20030217204650" -->
<!-- name="gts" -->
<!-- email="gts_2000@yahoo.com" -->
<!-- subject="RE: Performance enhancement with selegiline" -->
<!-- id="000001c2d6c5$b37eacc0$7f4a87d8@MyPC" -->
<!-- charset="us-ascii" -->
<!-- inreplyto="BMEDJIBJGLNDOOANGIDLMEPMCJAA.rafal@smigrodzki.org" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> gts (<a href="mailto:gts_2000@yahoo.com?Subject=RE:%20Performance%20enhancement%20with%20selegiline"><em>gts_2000@yahoo.com</em></a>)<br>
<strong>Date:</strong> Mon Feb 17 2003 - 13:46:50 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2897.html">Gary Miller: "RE: Performance enhancement with selegiline"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2895.html">Olga Bourlin: "Peter Singer's Ethics - Derived from Fact and Reason?"</a>
<li><strong>In reply to:</strong> <a href="2863.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="3090.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="3090.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2896">[ date ]</a>
<a href="index.html#2896">[ thread ]</a>
<a href="subject.html#2896">[ subject ]</a>
<a href="author.html#2896">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
Rafal wrote:
<br>
<em>&gt;&gt;&gt; ### I explained before but can do it again: selegiline did not slow
</em><br>
<em>&gt;&gt;&gt; the progression of symptoms, merely symptomatically delayed the time
</em><br>
<em>&gt;&gt;&gt; to levodopa, as shown by the loss of efficacy during washout.
</em><br>
<em>&gt;&gt; 
</em><br>
<em>&gt;&gt; I stand by my words. Selegiline delayed the time to which symptoms
</em><br>
<em>&gt;&gt; become severe enough to require treatment with levodopa. That is
</em><br>
<em>&gt;&gt; &quot;slowing the progression of Parkinson's disease symptoms&quot; by anyone's
</em><br>
<em>&gt;&gt; definition, Rafal.
</em><br>
<em>&gt; 
</em><br>
<em>&gt; ### No it isn't. The symptoms appeared at the same rate, but were
</em><br>
<em>&gt; delayed. 
</em><br>
<p>Uhh, excuse me but a delay in the appearance of parkinson's symptoms is
<br>
the same thing as &quot;slowing the progression of symptoms.&quot;
<br>
<p><em>&gt; I was referring to the absence of any influence on the
</em><br>
<em>&gt; progression of the underlying disease process. 
</em><br>
<p>I understand that, Rafal, but the statement of mine to which you are
<br>
objecting concerns the delay by selegiline of the *symptoms* of
<br>
parkinson's disease. 
<br>
<p>But anyway, as I was saying, this really isn't a support group for PD
<br>
patients. We need to take a broader view of selegiline from the
<br>
perspective of life-extensionists and transhumanists and extropians. It
<br>
is to them (to us) that I address my messages. 
<br>
<p>-gts
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2897.html">Gary Miller: "RE: Performance enhancement with selegiline"</a>
<li><strong>Previous message:</strong> <a href="2895.html">Olga Bourlin: "Peter Singer's Ethics - Derived from Fact and Reason?"</a>
<li><strong>In reply to:</strong> <a href="2863.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="3090.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="3090.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2896">[ date ]</a>
<a href="index.html#2896">[ thread ]</a>
<a href="subject.html#2896">[ subject ]</a>
<a href="author.html#2896">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Mon Feb 17 2003 - 13:48:03 MST
</em></small></p>
</body>
</html>
